Biomedical subjects

J Kurhanewicz

Publications and source records attributed to J Kurhanewicz.

At least 37 records · Page 2Linked to original sources

PubMed1998

Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging.

PURPOSE: To assess whether magnetic resonance (MR) spectroscopic imaging with MR imaging can improve prostate cancer localization in postbiopsy hemorrhage cases. MATERIALS AND METHODS: Records of 175 patients with prostate cancer were retrospectively reviewed; 42 patients (135 hemorrhagic sites) had spatially correlated biopsy data. Patients underwent both phased-array coil-endorectal coil MR imaging and three-dimensional MR spectroscopic imaging within 180 days after transrectal ultrasound (US)-guided biopsy. High-signal-intensity hemorrhage on T1-weighted images and corresponding high- or low-signal-intensity areas on T2-weighted images and the metabolic ratio (choline + creatine)/citrate were recorded. Cancer was identified as a low-signal-intensity area at T2-weighted MR imaging or a metabolite ratio greater than 3 standard deviations above normal at MR spectroscopic imaging. MR imaging, spectroscopic, and biopsy findings were compared. RESULTS: Forty-nine patients had postbiopsy hemorrhage. On T2-weighted images, a higher (P < .01) percentage of hemorrhagic sites demonstrated low signal intensity (80% [108 of 135 sites]), which is similar to the signal intensity seen with cancer. The addition of MR spectroscopic imaging to MR imaging resulted in a significant increase (P < .01) in the accuracy (52% to 75%) and specificity (26% to 66%) of tumor detection. CONCLUSION: The addition of MR spectroscopic imaging to MR imaging significantly improves the ability to determine the presence of prostate cancer and spatial extent when postbiopsy changes hinder interpretation with MR imaging alone.

Aged↗

PubMed1997

High spatial resolution and speed in MRSI.

The in vivo applications of magnetic resonance spectroscopic imaging (MRSI) have expanded significantly over the past 10 years and have reached the point where clinical trials are underway for a number of different diseases. One of the limiting factors in the widespread use of this technology has been the lack of widely available tools for obtaining data which are localized to sufficiently small tissue volumes to make an impact upon diagnosis and treatment planning. This is especially difficult within the timeframe of a clinical MR examination, which requires that both anatomic and metabolic data are acquired and processed. Recent advances in the hardware and software associated with clinical scanners have provided the potential for improvements in the spatial and time resolution of imaging and spectral data. The two areas which hold the most promise in terms of MRSI data are the use of phased array coils and the implementation of echo planar k-space sampling techniques. These could have immediate impact for 1H MRSI and may prove valuable for future applications of 31P MRSI.

Brain Neoplasms↗

PubMed1997

Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING).

A T1 insensitive solvent suppression technique-band selective inversion with gradient dephasing (BASING)-was developed to suppress water and lipids for 1H magnetic resonance spectroscopy (MRS). BASING, which consists of a frequency selective RF inversion pulse surrounded by spoiler gradient pulses of opposite signs, was used to dephase stopband resonances and minimally impact passband metabolites. Passband phase linearity was achieved with a dual BASING scheme. Using the Shinnar-Le Roux algorithm, a highpass filter was designed to suppress water and rephase the lactate methyl doublet independently of TE, and water/lipid bandstop filters were designed for the brain and prostate. Phantom and in vivo experimental 3D PRESS CSI data were acquired at 1.5 T to compare BASING with CHESS and STIR suppression. With BASING, the measured suppression factor was over 100 times higher than with CHESS or STIR causing baseline distortions to be removed. It was shown that BASING can be incorporated into a variety of sequences to offer improved suppression in the presence of B1 and T1 inhomogeneites.

Brain Chemistry↗

PubMed1996

Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy.

OBJECTIVES: To assess and compare the clinical usefulness of transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and three-dimensional proton magnetic resonance spectroscopic imaging (3-D MRSI) in detecting local recurrence of carcinoma of the prostate (CaP) in patients with detectable prostate-specific antigen (PSA) levels after cryosurgery. METHODS: In a prospective study, 25 patients who had undergone cryosurgery as primary treatment for CaP underwent endorectal MRI and 3-D MRSI, followed by TRUS-guided prostate biopsy. At the time of study, 20 patients had detectable PSA; the remaining 5 patients served as controls. All patients had random sextant and guided prostate biopsy for correlation with imaging and MR spectroscopic findings. RESULTS: In patients with detectable PSA, MRSI identified, location-for-location, all foci of CaP and benign prostatic tissue that were detected by prostate biopsy. MRSI identified more sites with CaP than did prostate biopsy, indicating a larger volume of cancer. In 2 patients with detectable PSA and negative prostate biopsy, MRSI identified 11 voxels with viable prostatic tissue. In patients with undetectable PSA, both MRSI and prostate biopsy showed necrosis. Ultrasound and MRI were very poor tools for identifying recurrent cancer and differentiating between viable and necrotic prostate tissue. CONCLUSIONS: 3-D MRSI is superior to TRUS and MRI in differentiating among CaP, BPH, and necrosis when local recurrence after cryosurgery is suspected. By providing chemical mapping of the prostate in contiguous voxels, the addition of spectroscopy to endorectal MRI increases the sensitivity for detection of local recurrence.

Aged↗

PubMed1996

Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.

PURPOSE: To evaluate if three-dimensional hydrogen-1 magnetic resonance spectroscopic imaging (3D MRSI) when combined with a clinical MR imaging examination could discriminate prostatic adenocarcinoma from normal prostatic zonal anatomy and benign prostatic hyperplasia (BPH) on the basis of observable metabolite levels. MATERIALS AND METHODS: Combined phased-array, endorectal MR imaging and 3D MRSI was performed in nine young healthy volunteers, five patients with BPH, and 85 patients with prostate cancer and BPH. Volume MR imaging and 3D MRSI data were analytically corrected for the reception profile of the endorectal and pelvic phased-array coils, aligned with the MR imaging data, and compared with postoperative pathologic histology findings. RESULTS: Statistically significant variations in metabolite levels with prostatic zonal anatomy, age, and pathologic condition were detected with a 3D MRSI examination added to a clinical MR imaging examination. Significantly higher choline levels and significantly lower citrate levels were observed in regions of cancer compared with BPH and normal peripheral zone tissues. The ratio (choline + creatine/citrate) in regions of cancer (2.1 +/- 1.3 [standard deviation]) had no overlap with normal peripheral zone values and minimal overlap with BPH values (0.61 +/- 0.21). An estimate of the spatial extent of prostate cancer was determined by generating metabolite images in which this metabolite ratio significantly exceeded normal peripheral zone values in multiple contiguous sections. CONCLUSION: These results suggest that a 3D MRSI examination added to a clinical MR imaging examination may help define the presence and spatial extent of prostate cancer.

Adenocarcinoma↗

PubMed1996

Prostate carcinoma: MR imaging findings after cryosurgery.

PURPOSE: To determine the morphologic changes in the prostate gland after cryosurgery and to assess the value of magnetic resonance (MR) imaging in detecting residual tumor. MATERIALS AND METHODS: Twenty-seven patients with prostate carcinoma underwent endorectal MR imaging after cryosurgery. Eighteen patients also underwent MR imaging before cryosurgery. MR findings were correlated with posttreatment clinical data, prostate-specific antigen level, and biopsy results. RESULTS: Mean prostate volume had decreased by 52% in patients examined 8 weeks or more after cryosurgery. Zonal differentiation was lost in 22 of 27 patients (81%). Areas of intraprostatic necrosis were identified in 14 of 27 patients (52%). A thick capsule enveloped the gland and neurovascular bundles in 24 of 27 patients (89%). Osteonecrosis of the symphysis pubis was seen in six of 27 patients (22%). Positive and negative predictive values for MR assessment of recurrent tumor were 44% and 73%, respectively. CONCLUSION: Cryosurgery-induced changes in the prostate gland preclude reliable detection of residual prostate carcinoma at MR imaging.

Aged↗

PubMed1996

Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.

PURPOSE: To determine, in patients with prostate cancer treated with cryosurgery, whether levels of choline and citrate measured at magnetic resonance (MR) spectroscopy can help discriminate regions of residual tumor from other prostatic tissues and necrosis. MATERIALS AND METHODS: Combined MR imaging and three-dimensional proton spectroscopic imaging were performed in 25 patients (mean age, 69 years) with prostate cancer who underwent cryosurgery. Volume imaging and spectroscopic data were analytically corrected for the reception profile of the endorectal and pelvic phased-array coils. Spectral data were aligned with the MR imaging data and compared with serum prostate-specific antigen levels and biopsy results. RESULTS: Histologically confirmed necrotic tissue (432 voxels) did not demonstrate any observable choline or citrate. The (choline + creatine)/ citrate values in regions of histologically confirmed benign prostatic hyperplasia (0.61 +/- 0.21 [standard deviation], 52 voxels) and cancer (2.4 +/- 1.0, 65 voxels) after cryosurgery were not statistically significantly different from those before therapy but were statistically significantly different from the ratio in necrotic tissue and from each other. The (choline + creatine)/citrate images threshold and overlaid in color on T2-weighted images yielded an estimate of the spatial extent of prostate cancer and benign prostatic hyperplasia. CONCLUSION: Volume MR imaging with MR spectroscopic imaging provided a noninvasive assessment of the presence and location of residual cancer after unsuccessful therapy and helped identify successful cryosurgery in patients who still had an elevated prostate-specific antigen level.

Aged↗

PubMed1996

Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging.

OBJECTIVE: The purpose of our study was to evaluate the effect of androgen deprivation therapy on the MR imaging findings of prostate gland anatomy and cancer pathology in men with prostatic cancer treated with hormonal ablation before radical prostatectomy. MATERIALS AND METHODS: Twenty-two patients (mean age, 66 years old) were divided into two groups: in group I (n=10), MR imaging studies were done before and after hormonal treatment; in group II (n=12), MR imaging studies were done only after hormonal treatment. MR imaging was performed on a 1.5 T-scanner (Signa; General Electric Medical Systems, Milwaukee, WI) and included transverse plane phased-array coil T1-weighted images (TR/TE, 600/12), combined endorectal phased-array coil transverse plane T1-weighted images, fast spin-echo T2-weighted (4000/102), and coronal plane fast spin-echo T2-weighted images. Image evaluation was by consensus and included assessment of the gland size, signal intensity, tumor depiction, extracapsular extension, seminal vesicle invasion, and overall staging accuracy (Jewett and Whitmore classification). MR imaging findings were correlated with pathologic findings of step section radical prostatectomy. RESULTS: After hormonal therapy, the volume of the prostate gland showed a mean decrease of 33.5% +/- 19.6% SD (range, 0-64%). Volume reduction in the transition zone (mean 29.2% +/- 22% SD) was less than in the peripheral zone (mean, 55.8% +/- 25.8% SD) (p < .05). On T2-weighted images, the peripheral zone showed homogeneous decreases in signal intensity in 13 of 22 (58%) patients. Compared with pathologic findings, the accuracy of tumor detection by MR imaging was 74% (98 of 132 sites). Tumor presence was overestimated in 32 of 132 (24%) sites. Overall staging accuracy after hormonal ablation was 68% (15 of 22). The positive predictive value and negative predictive value for extracapsular extension were 57% (13 of 23 sites) and 90% (19 of 21 sites), respectively, and for seminal vesicle invasion were 80% (8 of 10 sites) and 97% (33 of 34 sites), respectively. CONCLUSION: As detected by MR imaging, hormonal ablation caused a decrease in size and signal intensity of the prostate gland and seminal vesicles and overestimation of tumor presence and extracapsular extension.

Aged↗

PubMed1995

Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy.

OBJECTIVES: This study was designed to determine whether citrate levels detected by localized 1H spectroscopy could reliably discriminate regions of prostate adenocarcinoma from surrounding regions of normal peripheral zone and benign prostatic hyperplasia (BPH). METHODS: In 28 patients and 5 volunteers stimulated echo proton spectroscopy was used in conjunction with endorectal surface coils to obtain water-suppressed 1H spectra from regions of normal prostate peripheral zone, BPH, and prostate cancer. 1H spectra from prostate cancer patients were correlated with pathologic areas identified on T2-weighted endorectal coil magnetic resonance (MR) images and histologic study of the step-sectioned gland after surgery. RESULTS: The major finding of in vivo studies was consistently lower citrate levels in prostate cancer compared with BPH and normal prostate peripheral zone. This was reflected by significantly (P < 0.05) lower mean citrate/(creatine plus choline) peak area ratio observed for regions of cancer (0.67 +/- 0.17) compared with BPH (1.21 +/- 0.29) and normal peripheral zone (1.46 +/- 0.28). Moreover, there was no overlap of individual cancer and normal peripheral zone citrate ratios and no significant difference between citrate ratios in regions of normal peripheral zone in young volunteers (1.28 +/- 0.14) and age-matched patients (1.46 +/- 0.28). The observed alterations in vivo citrate levels were supported by citrate concentration data obtained from extracts of histologically proven samples of normal, benign, and malignant prostatic tissues removed at surgery. In vitro citrate levels in the normal peripheral zone (30.9 +/- 8.5 mumol/g wet weight) and BPH (46.3 +/- 5.4 mumol/g wet weight) were significantly higher than those for prostate cancer (3.74 +/- 0.54 mumol/g wet weight). CONCLUSIONS: These studies further demonstrate the potential of citrate as an in vivo marker for discriminating prostate cancer from surrounding regions of normal peripheral zone and BPH.

Adenocarcinoma↗

PubMed1995

Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images.

PURPOSE: To assess the frequency of changes in signal intensity after prostatic biopsy and the effect of these changes on the magnetic resonance (MR) imaging staging of prostate cancer. MATERIALS AND METHODS: Seventy-three patients with biopsy-proved prostate cancer were divided into two groups according to time between biopsy and imaging (less than and more than 21 days). The findings at MR imaging were compared with those at pathologic examination. RESULTS: Postbiopsy hemorrhage was detected in 21 of 26 (81%) patients who underwent imaging less than 21 days after biopsy and in 23 of 47 (49%) patients who underwent imaging more than 21 days after biopsy (P < .01). Postbiopsy changes persisted for as long as 4 1/2 months. Less than 21 days after biopsy, there was a tendency to overestimate tumor presence and extracapsular extension. After 21 days, tumor presence was underestimated but the positive predictive value for extracapsular extension was improved. Staging accuracy less than 21 days after biopsy was 46%; this improved to 83% after 21 days (P < .01). CONCLUSION: Staging accuracy is significantly improved when imaging is deferred for 21 days after biopsy.

Biopsy, Needle↗

PubMed1994

Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils.

PURPOSE: To compare the performance of pelvic phased-array (PPA) coils and integrated endorectal PPA coils in evaluation of local extent of prostate cancer. MATERIALS AND METHODS: Seventy-one men underwent magnetic resonance (MR) imaging within 3 weeks of radical prostatectomy. MR findings of tumor, extracapsular extension, seminal vesicle invasion, nodal involvement, and stage were compared with step-sectioned (3-4-mm intervals) whole-mounted pathologic specimens. Prospective consensus versus single-reader interpretation (kappa statistics) and PPA versus integrated endorectal PPA coils (McNemar test) were compared, and a rating scale of 1-6 was developed for analysis of receiver operating characteristics. Statistical significance was calculated at delta = .05. RESULTS: Comparison between consensus and single-reader image interpretation showed positive but poor agreement (kappa = .38) and no statistical significance. Staging accuracy was better (difference approached significance) for integrated endorectal PPA coils (77%) than for PPA coils (68%). CONCLUSION: The integrated endorectal PPA coil is better for evaluation of local prostatic cancer than is the PPA coil.

Humans↗

PubMed1994

31P magnetic resonance spectroscopy after combined hyperthermia and radiation.

Mechanisms of uveal melanoma response to therapy are poorly understood. There are a paucity of changes that have been detected immediately after tumor treatment to differentiate successful from ineffective therapy. In this study we used in vivo 31P magnetic resonance spectroscopy (MRS) to assess intra-tumor treatment alterations. The metabolic consequences of effective and ineffective levels of solitary hyperthermia and combined hyperthermia-radiation were investigated. We have previously noted a characteristic 31P MRS pattern with successful hyperthermia in this intraocular melanoma model. The metabolic response after effective or ineffective combined radiation/hyperthermia therapy was indistinguishable from solitary radiation therapy and opposite to that with successful hyperthermia therapy. In contrast to solitary hyperthermia therapy, early changes in 31P spectral ratios following radiation or combined hyperthermia/radiation therapy of uveal melanoma were not predictive of treatment response. Twenty-four to 48 hours after effective or ineffective radiation or combined treatment the Pi/beta-NTP ratio decreased significantly (delta Pi/beta-NTP = -0.433 +/- 0.08 and -0.478 +/- .13 and .10 +/- 0.2, respectively). There was over a 2.0 thermal enhancement of radiation with heat. The increased tumor cell death after combined therapy was reflected by a two-fold larger decrease in beta-NTP signal-to-noise (S/N).

Animals↗

PubMed1994

13-cis-retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells.

The purpose of this study was to examine the effects of 13-cis-retinoic acid (13-cis-RA) on the growth regulation of DU-145 human prostatic cancer cells. The results of these experiments demonstrate that cell growth and metastatic potential of DU-145 cells were significantly inhibited by 13-cis-RA (10 microM). In order to elucidate the possible molecular mechanisms of 13-cis-RA action on prostate cancer cells, we examined the expression of nuclear receptor genes (hRXR alpha) and found that 13-cis-RA treated cells showed higher mRNA expression for hRXR alpha nuclear receptors compared to untreated cells. To elucidate further the possible biochemical mechanisms associated with these alterations, we analyzed the phosphorous metabolites by MR spectroscopy and found that the major metabolites were PME, (PC, PE) and DPDE (UDP-GalNAc, UDP-GLcNAc). The DU-145 cells and xenografts, which were both treated with 13-cis-RA, showed a two-fold decrease in DPDE's, compared to their controls. The higher resolution spectra of perfused cells revealed that phosphocholine levels were twice as high in 13-cis-RA-treated DU-145 cells as compared to untreated cells. These investigations demonstrate for the first time that 13-cis-RA inhibits the growth of human prostatic cancer cells, and this inhibition is associated with an increase in hRXR alpha nuclear receptor gene expression and alterations in phosphorous metabolites detected by 31P MR spectroscopy.

Animals↗

PubMed1993

Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study.

The objectives of this study were to quantitatively verify the low levels of citrate previously observed in primary human prostatic adenocarcinomas and to determine whether citrate was further reduced in metastatic prostatic cancer. This was accomplished by comparison of citrate concentrations of DU 145 xenografts (a poorly differentiated human prostatic adenocarcinoma cell line grown in nude mice) with concentrations in primary human adenocarcinomas. Following in vivo 1H NMR studies of DU 145 xenografts, citrate concentrations of DU 145 xenografts and surgically removed primary prostatic adenocarcinoma tissue were determined by quantitative high resolution 1H NMR and enzymatic assay. The most significant findings of this study were that citrate concentrations in primary human adenocarcinomas (3.74 +/- 0.19 mumol/g wet weight) were significantly lower than those observed for normal and benign hyperplastic (BPH) prostatic tissues. Furthermore there was a further ten-fold reduction of citrate associated with DU 145 xenografts (0.31 +/- 0.028 mumole/g wet weight) compared with primary prostatic cancer. DU 145 xenografts also exhibited higher levels of uridine diphosphosugars and choline containing metabolites relative to primary prostatic adenocarcinomas. These findings support the hypothesis that citrate is low in primary prostatic cancer and further reduced in metastatic disease.

Adenocarcinoma↗

PubMed1993

Effect of glucose and confluency on phosphorus metabolites of perfused human prostatic adenocarcinoma cells as determined by 31P MRS.

A series of perfused cell 31P MRS studies were conducted using a well established human prostate adenocarcinoma cell line (DU 145) at different phases of growth, and exposed to varying glucose concentrations during growth. The spectral characteristics of perfused DU 145 cells were compared with the same cells grown in nude mice (xenografts). Perfused DU 145 cells had lower levels of inorganic phosphate and phosphocreative relative to in vivo nude mice xenografts. 31P MR spectra obtained from perfused cells at different phases of growth and exposed to varying glucose concentrations during grown suggest that increases in diphosphodiester levels are associated with high glucose concentrations and confluency. Perfused DU 145 cells grown in 5.5 mM glucose and harvested at log phase of growth best reflected the phosphorus MR spectra of the same cell line grown in nude mice.

Adenocarcinoma↗

PubMed1992

Magnetic resonance spectroscopy in prostate disease: diagnostic possibilities and future developments.

Magnetic resonance spectroscopy (MRS) is a relatively new technique for studying membrane and intracellular metabolic events occurring in cancer. A series of transrectal probes were used for performing MRS and subsequently for integrated MRS/magnetic resonance imaging (MRI) of the prostate. Studies using transrectal 31P/1H MRS showed that it can characterize metabolic differences between normal and malignant prostates. Specifically, malignant prostates are characterized by low levels of phosphocreatine and citrate and high levels of phosphomonoesters relative to normal glands. These findings were verified in biochemical studies of prostate biopsies. The images obtained by transrectal coil techniques were superior to images obtained by the conventional body coil technique. In the future, the integration of 1H imaging and multi-volume localization techniques (spectroscopic imaging) will allow the acquisition of metabolic maps of the prostate which may eventually be useful in diagnosis and in management of patients with prostate cancer.

Adenocarcinoma↗

PubMed1991

31P spectroscopy of the human prostate gland in vivo using a transrectal probe.

Using a transrectal probe, good quality 31P magnetic resonance spectroscopy of the human prostate was performed safely, consistently, and in a reasonable amount of time (average of 60 min). Initial results indicate that transrectal 31P MRS has the ability to characterize the phosphorylated metabolites of normal, hyperplastic, and malignant prostates. This study demonstrated that malignant prostates are characterized by significantly decreased levels of phosphocreatine (PCr) and increased levels of phosphomonoesters (PME) as compared to healthy prostates.

Adult↗

PubMed1991

Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: a preliminary report.

We assessed the ability of 31phosphorus (31P) transrectal magnetic resonance spectroscopy to characterize normal human prostates as well as prostates with benign and malignant neoplasms. With a transrectal probe that we devised for surface coil spectroscopy we studied 15 individuals with normal (5), benign hyperplastic (4) and malignant (6) prostates. Digital rectal examination, transrectal ultrasonography and magnetic resonance imaging were used to aid in accurate positioning of the transrectal probe against the region of interest within the prostate. The major findings of the in vivo studies were that normal prostates had phosphocreatine-to-adenosine triphosphate (ATP) ratios of 1.2 +/- 0.2, phosphomonoester-to-beta-ATP ratios of 1.1 +/- 0.1 and phosphomonoester-to-phosphocreatine ratios of 0.9 +/- 0.1. Malignant prostates had phosphocreatine-to-beta-ATP ratios that were lower (0.7 +/- 0.1) than those of normal prostates (p less than 0.02) or prostates with benign hyperplasia (1.1 +/- 0.2, p less than 0.01). Malignant prostates had phosphomonoester-to-beta-ATP ratios (1.8 +/- 0.2) that were higher than that of normal prostates (p less than 0.02). Using the phosphomonoester-to-phosphocreatine ratio, it was possible to differentiate metabolically malignant (2.7 +/- 0.3) from normal prostates (p less than 0.001), with no overlap of individual ratios. The mean phosphomonoester-to-phosphocreatine ratio (1.5 +/- 0.5) of prostates with benign hyperplasia was midway between the normal and malignant ratios, and there was overlap between individual phosphomonoester-to-phosphocreatine ratios of benign prostatic hyperplasia glands with that of normal and malignant glands. To verify the in vivo results, we performed high resolution magnetic resonance spectroscopy on perchloric acid extracts of benign prostatic hyperplasia tissue obtained at operation and on a human prostatic cancer cell line DU145. The extract results confirmed the differences in metabolite ratios observed in vivo. We conclude that transrectal 31P magnetic resonance spectroscopy can characterize metabolic differences between the normal and malignant prostate.

Adult↗